BioAgilytix Team Q&A: Meet Dave Williams, Director, Bioanalytical Operations at BioAgilytix
In this Team Q&A session, Dave Williams, Director, Bioanalytical Operations at BioAgilytix, talks with us about why he made the move from Kansas City to…
BioAgilytix Team Q&A: Meet Beth Heinz, Vice President of Global Business Development at BioAgilytix
In this Q&A session, we speak to Beth Heinz, Vice President of Global Business Development at BioAgilytix, as she discusses the evolution of her career…
BioAgilytix Team Q&A: Meet William Hunter, Director of Business Development and Global Key Accounts at BioAgilytix Europe
In this Q&A session, we get to know William Hunter, Director of Business Development and Global Key Accounts at BioAgilytix Europe, as he discusses why…
Immuno-oncology in 2018: Overcoming Challenges to Revolutionize Cancer Treatment
Many immuno-oncology therapies are seeing success and showing promise for the future, including CAR-T cells, tumor-infiltrating lymphocytes (TILs), checkpoint inhibitors, and natural killer cell therapies.…
The Future of Bioanalytical Outsourcing: What It Means for Our Industry
Today’s pharmaceutical and biotechnology organizations must constantly innovate and evolve to meet novel requirements of developing increasingly effective (but increasingly complex) biotherapeutic innovations. This has…
Biomarkers and Immunogenicity in the Spotlight at the 2016 10th Workshop on Recent Issues in Bioanalysis
The whitepaper based on discussions at the 10th Workshop on Recent Issues in Bioanalysis (WRIB) has been published! Everyone who participated, are very excited to…